JOURNAL LINFORMATIONBusiness Directories,Company Directories

Company Name: Corporate Name:	JOURNAL LINFORMATION
Company Title:
Company Description:
Keywords to Search:
Company Address:	135 Av Doucet,MONT-JOLI,QC,Canada
ZIP Code: Postal Code:	G5H1R6
Telephone Number:	4187754381
Fax Number:	4187757768
Website:
Email:
USA SIC Code(Standard Industrial Classification Code):	271101
USA SIC Description:	Newspapers (Publishers)
Number of Employees:	20 to 49
Sales Amount:	$5 to 10 million
Credit History: Credit Report:	Excellent
Contact Person:	Francis Dersrosier
Remove my name

Company Directories & Business Directories

copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)

Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Previous company profile:
LHIBOU-COUP INC
JULIEN THERIAULT CONSTRUCTION
JOURNAL LINFORMATION HEBDO REG

Next company profile:
JOLY, DIANE OD
JEAN-PIERRE ST-AMAND INC
J P REPARATION TRANS METAL

Company News:

The New England Journal of Medicine | Research Review Articles on . . .
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations in the gene encoding ERα
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
Methods In a phase 3, randomized, controlled trial, we assigned adults with biopsy-proven active lupus nephritis in a 1:1 ratio to receive obinutuzumab in one of two dose schedules (1000 mg on day
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP
Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer
Background First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF V600E–mutated metastatic
Current Issue | New England Journal of Medicine
Explore the current issue of The New England Journal of Medicine (Vol 393 No 21)
Lorundrostat Efficacy and Safety in Patients with Uncontrolled . . .
Background Aldosterone dysregulation contributes to hypertension Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy and safety in patients with hypertension are limited
Medical Management and Revascularization for Asymptomatic Carotid . . .
Improvements in medical therapy, carotid-artery stenting, and carotid endarterectomy call into question the preferred management of asymptomatic carotid stenosis Whether adding revascularization t